Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer
- Status
- UNKNOWN
- Phase
- N/A
Clinical Trials Related to Palbociclib
Related studies linked through entity extraction aliases.
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
- Status
- TERMINATED
- Phase
- PHASE2
High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Palbociclib + Ganitumab In Ewing Sarcoma
- Status
- TERMINATED
- Phase
- PHASE2
Analysis of Palbociclib Treatment in Patients With Advanced Breast Cancer Within a Compassionate Use Programe
- Status
- COMPLETED
- Phase
- N/A
A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
UK Ibrance Patient Program (IPP) Study
- Status
- COMPLETED
- Phase
- N/A
Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Status
- TERMINATED
- Phase
- PHASE1
Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor
- Status
- COMPLETED
- Phase
- PHASE1
PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)
- Status
- COMPLETED
- Phase
- PHASE2